The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Midazolam 5mg/mL (5mg/1mL) solution for injection (Aguettant, France)
Section 19A approved medicine
Midazolam 5mg/mL (5mg/1mL) solution for injection (Aguettant, France)
Section 19A approval holder
Aborns Pharmacuticals Pty Ltd ABN 80 625 808 193
Phone
1300 117 772
Approved until
Status
Current
Medicines in short supply/unavailable
HYPNOVEL midazolam 5mg/1mL (as hydrochloride) injection ampoule - ARTG 13726
MIDAZOLAM VIATRIS 5mg/1mL midazolam solution for injection ampoule - ARTG 160207
Pfizer (Australia) MIDAZOLAM INJECTION midazolam 5mg/1mL injection ampoule - ARTG 72213
MIDAZOLAM VIATRIS 5mg/1mL midazolam solution for injection ampoule - ARTG 160207
Pfizer (Australia) MIDAZOLAM INJECTION midazolam 5mg/1mL injection ampoule - ARTG 72213
Indication(s)
- Intravenously as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac cathetherization, either alone or in conjunction with a narcotic;
- Intravenously for induction of anaesthesia, preliminary to administration of other anaesthetic agents. With the use of a narcotic premedicant, induction of anaesthesia can be attained with narrower dose range and in a shorter period of time;
- Sedation in intensive care units by intravenous intermittent administration or continuous infusion;
- Intramuscularly for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.
Images
